J
J. Gregory Cairncross
Researcher at University of Calgary
Publications - 141
Citations - 41100
J. Gregory Cairncross is an academic researcher from University of Calgary. The author has contributed to research in topics: Temozolomide & Glioma. The author has an hindex of 50, co-authored 134 publications receiving 35909 citations. Previous affiliations of J. Gregory Cairncross include University of Western Ontario & Foothills Medical Centre.
Papers
More filters
Journal ArticleDOI
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Roger Stupp,Warren P. Mason,Martin J. van den Bent,Michael Weller,Barbara Fisher,Martin J.B. Taphoorn,Karl Belanger,Alba A. Brandes,Christine Marosi,Ulrich Bogdahn,Jürgen Curschmann,Robert C. Janzer,Samuel K. Ludwin,Thierry Gorlia,Anouk Allgeier,Denis Lacombe,J. Gregory Cairncross,Elizabeth Eisenhauer,René O. Mirimanoff +18 more
TL;DR: The addition of temozolomide to radiotherapy for newly diagnosed glioblastoma resulted in a clinically meaningful and statistically significant survival benefit with minimal additional toxicity.
Journal ArticleDOI
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp,Monika E. Hegi,Warren P. Mason,Martin J. van den Bent,Martin J.B. Taphoorn,Robert C. Janzer,Samuel K. Ludwin,Anouk Allgeier,Barbara Fisher,Karl Belanger,Peter Hau,Alba A. Brandes,J.M.M. Gijtenbeek,Christine Marosi,Charles J. Vecht,Karima Mokhtari,Pieter Wesseling,Salvador Villà,Elizabeth Eisenhauer,Thierry Gorlia,Michael Weller,Denis Lacombe,J. Gregory Cairncross,René-Olivier Mirimanoff +23 more
TL;DR: Benefits of adjuvant temozolomide with radiotherapy lasted throughout 5 years of follow-up, and a benefit of combined therapy was recorded in all clinical prognostic subgroups, including patients aged 60-70 years.
Journal ArticleDOI
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Monika E. Hegi,Annie-Claire Diserens,Thierry Gorlia,Marie-France Hamou,Nicolas de Tribolet,Nicolas de Tribolet,Michael Weller,Johan M. Kros,Johannes A. Hainfellner,Warren P. Mason,Luigi Mariani,Jacoline E C Bromberg,Peter Hau,René O. Mirimanoff,J. Gregory Cairncross,Robert C. Janzer,Roger Stupp +16 more
TL;DR: Patients with glioblastoma containing a methylated MGMT promoter benefited from temozolomide, whereas those who did not have a methylation of theMGMT promoter did notHave such a benefit and were assigned to only radiotherapy.
Journal Article
Gene expression-based classification of malignant gliomas correlates better with survival than histological classification.
Catherine L. Nutt,D. R. Mani,Rebecca A. Betensky,Pablo Tamayo,J. Gregory Cairncross,Christine Ladd,Ute Pohl,Christian Hartmann,Margaret McLaughlin,Tracy T. Batchelor,Peter McL. Black,Andreas von Deimling,Scott L. Pomeroy,Todd R. Golub,Todd R. Golub,David N. Louis +15 more
TL;DR: It is suggested that class prediction models, based on defined molecular profiles, classify diagnostically challenging malignant gliomas in a manner that better correlates with clinical outcome than does standard pathology.
Journal ArticleDOI
Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma
James Perry,Normand Laperriere,Christopher J. O'Callaghan,Alba A. Brandes,Johan Menten,Claire Phillips,Michael Fay,Michael Fay,Ryo Nishikawa,J. Gregory Cairncross,Wilson Roa,David Osoba,John P. Rossiter,Arjun Sahgal,H Hirte,Florence Laigle-Donadey,Enrico Franceschi,Olivier Chinot,Vassilis Golfinopoulos,L. Fariselli,Antje Wick,Loïc Feuvret,Michael Back,Michael Tills,Chad Winch,Brigitta G. Baumert,Wolfgang Wick,Keyue Ding,Warren P. Mason +28 more
TL;DR: In elderly patients with glioblastoma, the addition of temozolomide to short‐course radiotherapy resulted in longer survival than short‐ Course radiotherapy alone.